Epidiolex

Shares of GW Pharmaceuticals plc (NASDAQ: GWPH) sold off Tuesday after the release of an abstract presented at the American Epilepsy Society meeting. The abstract showed evidence of interaction between GW Pharma's lead anti-epilepsy treatment, Epidiolex, and several other anti-epilepsy drugs...

The American Epilepsy Society (AES) annual meeting is scheduled to be held between December 2 and 6, during which GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) will present on its lead anti-epilepsy drug Epidiolex, providing data from the first two positive Phase 3 studies. What To Expect The...

The lead candidate of GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH), Epidiolex, has yielded positive results in three Phase III studies in two severe orphan epilepsies. “We anticipate a solid launch trajectory,” Goldman Sachs’ Salveen Richter said in a report. He initiated...

Leerink resumed coverage on GW Pharmaceuticals PLC (NASDAQ: GWPH) in anticipation of FDA approval for Epidiolex. Analyst Paul Matteis expressed an Outperform Rating, and set the firm’s price target at $162. Matteis primarily cited the FDA’s pending approval of Epidiolex, and...

The stocks of pharmaceutical companies often trade in sympathy with one another. It’s common for companies working on similar and/or competing drugs to trade in tandem or inversely when one company gets major news about one of its drug candidates. For example, if a drug candidate gets...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH), a developer of cannabinoid prescription medicines, saw its stock surge Monday after the company reported positive results from a clinical study. Wall Street took notice with some firms reaffirming their bullish stance on the stock and placing price...

GW Pharmaceuticals PLC (NASDAQ: GWPH)'s stock gained more than 17 percent Monday following the company's announcement of a second successful pivotal trial in an ongoing Phase 3 trial exploring its lead cannabinoid product, Epidiolex. GW Pharma's strong gains helped boost shares of...

Shares of GW Pharmaceuticals PLC (NASDAQ: GWPH) were trading higher by more than 17 percent Monday, but analysts at Cantor Fitzgerald believe the surge has just begun. GW Pharma announced a second successful pivotal trial in an ongoing Phase 3 trial which explores Epidiolex, its lead...

Shares of GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH), a developer of cannabinoid prescription medicines, spiked by more than 10 percent Monday morning following the company's announcement that Epidiolex achieved a primary endpoint in a Phase 3 clinical study. Epidiolex, GW Pharma's lead...

GW Pharmaceuticals plc (NASDAQ: GWPH) revealed Epidiolex has achieved primary endpoint in treating Lennox-Gastaut syndrome. The positive results came from its randomized, double-blind and placebo-controlled final stage clinical study. Earlier in June, the company disclosed favorable results...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) has dipped below $85 for the first time since June and is now on the brink of a technical breakdown. After a huge jump back in March following positive Phase 3 data on Epidiolex, the stock has traded in the bullish channel included on the chart below...

GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) has risen to $91.57 since its previous Vetr rating of 2.5 stars was issued two days ago. On Friday, the Vetr community upgraded their rating to three stars. The British pharmaceutical company rallied on Tuesday on the release of positive data from their...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)'s Epidiolex met primary endpoint in the phase three pivotal trial results for the treatment of Lennox-Gastaut Syndrome. The primary endpoint was achieved with superior statistical significance demonstrating that Epidiolex treatment reduces drop...

Cantor Fitzgerald's Elemer Piros is positive on GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH)'s technology value of its drug portfolio and estimated year-end 2016 cash position. He has a bullish view on the potential for Epidiolex following the published anecdotal evidence on the impact to...

Shares of GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) are up nearly 120 percent in early Monday trading after the company announced positive Phase III data on Epidiolex. The study found that the drug significantly reduced seizures in children suffering from Dravet Syndrome, a condition for which...